-
Product Insights
Hyperparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperparathyroidism - Drugs In Development, 2023’, provides an overview of the Hyperparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Secondary Hyperparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Hyperparathyroidism - Drugs In Development, 2023’, provides an overview of the Secondary Hyperparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Product Insights
Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Secondary hyperparathyroidism occurs when the parathyroid glands in the neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints, and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy. The Secondary Hyperparathyroidism drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2019 PharmSource Edition
This report is the 9th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Sector Analysis
Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD) – Competitive Landscape to 2027
Chronic Kidney Disease–Mineral Bone Disorders (CKD-MBD) is one of the many complications associated with overall CKD. The systemic disorder is identified from high parathyroid hormone and disrupted K+/Ca2+ levels caused by a decreasing glomerular filtration rate (GFR) due to renal impairment. This report provides an assessment of the pipeline, clinical, and commercial landscape of CKD-MBD. Overall, GlobalData expects minimal changes to overall disease treatment, with exceptions being the launch of the novel NHE3 and novel CASR in the US and...
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2020 PharmSource Edition
This report is the 10th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.